Regenxbio (RGNX) Surges 18.3%: Is This an Indication of Further Gains?
Here's Why Sarepta (SRPT) Stock Price Surged 57% YTD
Regenxbio(RGNX.US) Director Sells US$112.69K in Common Stock
$Regenxbio(RGNX.US)$ Director KARABELAS ARGERIS N sold 10,000 shares of common stock on Jul 1, 2024 at an average price of $11.2691 for a total value of $112.69K.Source: Announcement What is statement
Why Did Analysts Maintain a Bullish Stance on REGENXBIO Inc. (RGNX) Despite Decline In Its Revenue Growth?
Why Is Clearside Biomedical Stock Gaining Today?
Oppenheimer initiated coverage on Clearside Biomedical Inc (NASDAQ:CLSD), a biopharmaceutical company focused on delivering therapies to the back of the eye through the suprachoroidal (SCS) space.Oppe
Regenxbio (RGNX) Soars 6.4%: Is Further Upside Left in the Stock?
Regenxbio Enrolling New Group for Phase 1/2 Duchenne Muscular Dystrophy Trial
Regenxbio (RGNX) said Monday that it started the enrollment of a new group of patients aged 1 year to 3 years old for the phase 1/2 trial of RGX-202 in boys with Duchenne muscular dystrophy. The compa
Express News | REGENXBIO Expands Its AFFINITY DUCHENNE Trial To Include A New Cohort Of Younger Patients
Express News | Regenxbio Inc: On Track to Initiate Pivotal Trial in Late Q3 to Early Q4 2024
Express News | Regenxbio Announces Expansion of Affinity Duchenne® Trial to Include a New Cohort of Younger Patients
BofA Securities Maintains Regenxbio(RGNX.US) With Buy Rating, Cuts Target Price to $33
BofA Securities analyst Alec Stranahan maintains $Regenxbio(RGNX.US)$ with a buy rating, and adjusts the target price from $35 to $33.According to TipRanks data, the analyst has a success rate of 48.9
FDA Approves Expanded Use For Sarepta's Rare Muscular Dystrophy Gene Therapy
Thursday, the FDA approved labeled indication for Sarepta Therapeutics Inc's (NASDAQ:SRPT) Elevidys (delandistrogene moxeparvovec-rokl) to include individuals with Duchenne muscular dystrophy (DMD) wi
H.C. Wainwright Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $38
H.C. Wainwright analyst Yi Chen maintains $Regenxbio(RGNX.US)$ with a buy rating, and maintains the target price at $38.According to TipRanks data, the analyst has a success rate of 22.9% and a total
Express News | HC Wainwright & Co. Reiterates Buy on Regenxbio, Maintains $38 Price Target
Regenxbio Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/20/2024 211.22% HC Wainwright & Co. $38 → $38 Reiterates Buy → Buy 06/07/2024 211.22% Goldman Sachs → $
RBC Capital Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $35
RBC Capital analyst Luca Issi maintains $Regenxbio(RGNX.US)$ with a buy rating, and maintains the target price at $35.According to TipRanks data, the analyst has a success rate of 20.0% and a total av
Stifel Maintains Regenxbio(RGNX.US) With Buy Rating
Stifel analyst Annabel Samimy maintains $Regenxbio(RGNX.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 45.5% and a total average return of 8.2% over the past year
REGENXBIO Inc.'s (NASDAQ:RGNX) 27% Dip In Price Shows Sentiment Is Matching Revenues
Unfortunately for some shareholders, the REGENXBIO Inc. (NASDAQ:RGNX) share price has dived 27% in the last thirty days, prolonging recent pain. Instead of being rewarded, shareholders who have alr
Regenxbio Reports 'Successful' Meeting With FDA For RGX-121
Regenxbio (RGNX) said Tuesday it has completed a "successful" pre-biologics license application meeting with the US Food and Drug Administration for RGX-121 for the treatment of Mucopolysaccharidosis
Express News | Regenxbio Concludes Pre-biologics License Application Meeting For RGX-121 For Mucopolysaccharidosis Type II, Where It Finalized Details Of Its Application With The FDA, Expects To Initiate Submission Of A Rolling BLA In Q3 Of 2024